McKesson Corporation MCK
866.64
(2.72)
(0.31%)
as of 25 Sep
- Market cap
- $101.8B
- P/E
- 23.1×
Follow MCK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
McKesson Corporation (MCK) EBITDA
McKesson Corporation's EBITDA for fiscal 2026 was $6.9B, up 37.2% from $5.1B in fiscal 2025. Over the twelve months to 30 June 2026 it was $7.3B. Over the past ten years it has ranged from −$3.9B (fiscal 2021) to $8.3B (fiscal 2017); the current reading is higher than 92% of that period. McKesson Corporation ranks 1st of 10 Medical Distribution companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $6.9B | 37.23% |
| FY2025 | $5.1B | 11.31% |
| FY2024 | $4.5B | (8.92%) |
| FY2023 | $5.0B | 78.31% |
| FY2022 | $2.8B | — |
| FY2021 | −$3.9B | — |
| FY2020 | $3.6B | (9.30%) |
| FY2019 | $3.9B | (0.41%) |
| FY2018 | $3.9B | (52.78%) |
| FY2017 | $8.3B | 87.52% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.5B | (35.46%) |
| Mar 2026 | $2.3B | 29.83% |
| Dec 2025 | $1.8B | 13.29% |
| Sep 2025 | $1.6B | 33.70% |
| 42 more quarters | Free account |
Against its own ten years
Low −$3.9B
High $8.3B
Ten-year median
$4.3B
Current reading's percentile
92
EBITDA against peers
| Company | EBITDA |
|---|---|
| MCK McKesson Corporation | $7.3B |
| COR Cencora, Inc. compare | $4.1B |
| CAH Cardinal Health, Inc. compare | $3.6B |
| HSIC Henry Schein, Inc. compare | $1.0B |
| ACH Accendra Health, Inc. compare | $285.4M |
| YI 111, Inc. Sponsored ADR compare | −$3.3M |
| COSM Cosmos Health Inc. compare | −$16.9M |
| FOCL FocalTherics compare | −$25.3M |
| AHG Akso Health Group Sponsored ADR compare | −$30.3M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MCK
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement